Evidence map›Paper›PMID 25504222›Full record

ArticlePloS one2014

The clinical significance of DC-SIGN and DC-SIGNR, which are novel markers expressed in human colon cancer.

Yanmei Jiang, Changfu Zhang, Kai Chen, Zhe Chen, Zhigang Sun, Zhuqing Zhang, Dongbing Ding, Shuangyi Ren, Yunfei Zuo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Markers of metastatic colorectal cancer.Przeglad gastroenterologiczny · 2020
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yanmei JiangDepartment of Clinical Biochemistry, College of Laboratory Diagnostic Medicine, Dalian Medical University, Dalian, 116044, China; Department of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
Changfu ZhangDepartment of Clinical Biochemistry, College of Laboratory Diagnostic Medicine, Dalian Medical University, Dalian, 116044, China; Department of Neurosurgery, the First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
Kai ChenDepartment of Surgery, the Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China.
Zhe ChenDepartment of Surgery, the Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China.
Zhigang SunDepartment of Clinical Laboratory, the First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.
Zhuqing ZhangDepartment of Clinical Biochemistry, College of Laboratory Diagnostic Medicine, Dalian Medical University, Dalian, 116044, China.
Dongbing DingDepartment of Surgery, the Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China.
Shuangyi RenDepartment of Surgery, the Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China.
Yunfei ZuoDepartment of Clinical Biochemistry, College of Laboratory Diagnostic Medicine, Dalian Medical University, Dalian, 116044, China.
Dalian Medical University · CNSecond Affiliated Hospital of Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColon cancer has always been diagnosed at a late stage, which is associated with poor prognosis. The currently used serum tumor markers CEA and CA19-9 display low sensitivity and specificity and may not have diagnostic value in early stage colon cancer. Thus, there is an urgent need to identify novel serum biomarkers for use in the early detection of colon cancer.

methodsIn this study, the expression of DC-SIGN and DC-SIGNR in serum was detected by enzyme-linked immunosorbent assay (ELISA). DC-SIGN and DC-SIGNR expression was detected in cancer tissues by immunohistochemistry (IHC).

resultsThe level of sDC-SIGN was lower in patients than in the healthy controls, while the level of sDC-SIGNR in patients was higher than in the healthy controls. Both sDC-SIGN and sDC-SIGNR had diagnostic significances for cancer patients, and the combined diagnosis of these two markers was higher than both of them alone. Furthermore, there were significant differences between both sDC-SIGN and sDC-SIGNR in stage I/II patients and the healthy controls. Moreover, high sDC-SIGN level was accompanied with the long survival time. Additionally, DC-SIGNR was negative in the cancer foci and matched normal colon tissues but was weakly positive between the cancer foci. DC-SIGN staining was faint in matched normal colon tissues, strong in the tumor stroma and the invasive margin of colon cancer tissues, and negatively correlated with the sDC-SIGN level in serum from the same patient. Interestingly, the percent survival of patients with a DC-SIGN mean density of>0.001219 (the upper 95% confidence interval of matched normal colon tissues) was higher than for all other patients.

conclusionDC-SIGN and DC-SIGNR are blood-based molecular markers that can potentially be used for the diagnosis of early stage patients. Moreover, expression of DC-SIGN in serum and cancer tissues may affect the survival time for colon cancer patients.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBiomarkers, TumorCarcinoembryonic AntigenCell Adhesion MoleculesColonic NeoplasmsDC-Specific ICAM-3 Grabbing NonintegrinEarly Detection of CancerFemaleHumansIntestinal MucosaLectins, C-TypeMaleMiddle AgedBiomarkers, TumorCarcinoembryonic AntigenCell Adhesion MoleculesCLEC4M protein, humanDC-Specific ICAM-3 Grabbing NonintegrinLectins, C-TypeReceptors, Cell Surface

Identifiers

PMID25504222
PMCPMC4264775
OpenAlexW2085425985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.